Single Time Point Whole-Body Tumour Dosimetry as an Independent Prognostic Biomarker for Treatment Outcome in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Lutetium-177 [177Lu]Lu-PSMA-617

被引：0
|
作者：
Eifer, M. [1 ,2 ,3 ,4 ]
Papa, N. [1 ,2 ]
Kashyap, R. [1 ,2 ,5 ]
Buteau, J. P. [1 ,2 ,5 ]
McIntosh, L. [1 ,2 ]
Alipour, R. [1 ,2 ,5 ]
Azad, A. A. [5 ,6 ]
Akhurst, T. [1 ,2 ]
Cardin, A. [1 ,2 ,5 ]
Chen, D. [1 ,2 ]
Emmerson, B. [1 ,2 ]
Fettke, H. [5 ,7 ]
Haskali, M. [1 ,2 ,5 ]
Jewell, K. [1 ,2 ,5 ]
Kong, G. [1 ,2 ,5 ]
Kostos, L. [5 ,6 ]
Kumar, A. S. Ravi [1 ,2 ,5 ]
Macfarlane, L. [1 ,2 ]
Medhurst, E. [1 ,2 ,5 ]
Murphy, D. G. [5 ,8 ]
Saghebi, J. [1 ,2 ,5 ]
Sandhu, S. [5 ,6 ]
Tran, B. [5 ,6 ]
Jackson, P. [1 ,2 ,5 ]
Hofman, M. S. [1 ,2 ,5 ]
机构：
[1] Peter MacCallum Canc Ctr, Canc Imaging, Mol Imaging & Therapeut Nucl Med, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Prostate Canc Theranost & Imaging Ctr Excellence, Melbourne, Vic, Australia
[3] Chaim Sheba Med Ctr, Dept Diagnost Imaging, Ramat Gan, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[5] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[6] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[7] Peter MacCallum Canc Ctr, Canc Res Div, Melbourne, Vic, Australia
[8] Peter MacCallum Canc Ctr, Div Canc Surg, Melbourne, Vic, Australia
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-578
引用
收藏
页码：S281 / S281
页数：1
相关论文
共 50 条
  • [1] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Houede, Nadine
    Hebert, Kevin
    LANCET ONCOLOGY, 2024, 25 (05): : 531 - 533
  • [2] Personalized dosimetry assessment of [177Lu]Lu-PSMA-617 radioligand therapy in the management of metastatic castration-resistant prostate cancer
    Kazemi-Jahromi, Mahmood
    Yazdani, Elmira
    Karamzade-Ziarati, Najme
    Asadi, Mahboobeh
    Sadeghi, Mahdi
    Geramifar, Parham
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2024, 100 (11) : 1551 - 1559
  • [3] Castration-resistant prostate cancer: [177Lu]Lu-PSMA-617 versus cabazitaxel Comment
    Todenhoefer, Tilman
    AKTUELLE UROLOGIE, 2023, 54 (04)
  • [4] Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy
    Ahmadzadehfar, Hojjat
    Schlolaut, Stephan
    Fimmers, Rolf
    Yordanova, Anna
    Hirzebruch, Stefan
    Schlenkhoff, Carl
    Gaertner, Florian C.
    Awang, Zool Hilmi
    Hauser, Stefan
    Essler, Markus
    ONCOTARGET, 2017, 8 (61) : 103108 - 103116
  • [5] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Philipp E. Hartrampf
    Franz-Xaver Weinzierl
    Andreas K. Buck
    Steven P. Rowe
    Takahiro Higuchi
    Anna Katharina Seitz
    Hubert Kübler
    Andreas Schirbel
    Markus Essler
    Ralph A. Bundschuh
    Rudolf A. Werner
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3269 - 3276
  • [6] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Hartrampf, Philipp E.
    Weinzierl, Franz-Xaver
    Buck, Andreas K.
    Rowe, Steven P.
    Higuchi, Takahiro
    Seitz, Anna Katharina
    Kuebler, Hubert
    Schirbel, Andreas
    Essler, Markus
    Bundschuh, Ralph A.
    Werner, Rudolf A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (09) : 3269 - 3276
  • [7] Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
    Justin Ferdinandus
    John Violet
    Shahneen Sandhu
    Rodney J. Hicks
    Aravind S. Ravi Kumar
    Amir Iravani
    Grace Kong
    Tim Akhurst
    Sue Ping Thang
    Declan G. Murphy
    Scott Williams
    Michael S. Hofman
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 2322 - 2327
  • [8] Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
    Ferdinandus, Justin
    Violet, John
    Sandhu, Shahneen
    Hicks, Rodney J.
    Ravi Kumar, Aravind S.
    Iravani, Amir
    Kong, Grace
    Akhurst, Tim
    Thang, Sue Ping
    Murphy, Declan G.
    Williams, Scott
    Hofman, Michael S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (10) : 2322 - 2327
  • [9] Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
    Anna Yordanova
    Paula Linden
    Stefan Hauser
    Michael Meisenheimer
    Stefan Kürpig
    Georg Feldmann
    Florian C. Gaertner
    Markus Essler
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1073 - 1080
  • [10] Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
    Yordanova, Anna
    Linden, Paula
    Hauser, Stefan
    Meisenheimer, Michael
    Kuerpig, Stefan
    Feldmann, Georg
    Gaertner, Florian C.
    Essler, Markus
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (05) : 1073 - 1080
12345